Concord Drugs Ltd (538965)
Latest quarterly results (Q4 FY26)
In its latest reported quarter, Q4 FY26, Concord Drugs' revenue was ₹37.9 Cr (+264.8% year on year, +123.1% on the previous quarter), and net profit ₹0.5 Cr; the operating margin was 4.0%.
| Q4 FY26 (₹ Cr) | Value | YoY vs Q4 FY25 | QoQ |
|---|---|---|---|
| Revenue | ₹37.9 | +264.8% | +123.1% |
| Operating profit | ₹1.5 | +42.9% | +59.6% |
| Net profit | ₹0.5 | — | +140.9% |
| EPS (₹) | 0.40 | +900.0% | +135.3% |
| Operating margin | 4.0% | — | — |
📢 Recent Corporate Announcements
Concord Drugs Ltd reported a strong start to FY27, with consolidated net profit jumping to ₹1.11 Cr in Q1 (June 2026) from ₹0.12 Cr in the same quarter last year. Revenue from operations grew 54% YoY to ₹20.95 Cr, although it saw a sequential decline from the ₹37.90 Cr reported in March 2026. A key highlight is the improvement in EPS to ₹0.85 from ₹0.12 YoY, despite a 33% increase in equity share capital following a preferential allotment in March 2026. The company's quarterly profit now matches its entire FY26 annual profit of ₹1.06 Cr.
- Consolidated Net Profit surged 825% YoY to ₹1.11 Cr from ₹0.12 Cr in June 2025
- Revenue from operations increased 54% YoY to ₹20.95 Cr compared to ₹13.61 Cr in the previous year
- EPS improved to ₹0.85 from ₹0.12 YoY, despite a 33% increase in equity share base
- Finance costs reduced to ₹39.61 lakhs from ₹49.00 lakhs in the year-ago period
- Subsidiary Proton Remedies Private Limited contributed ₹36.54 lakhs to the quarterly revenue
Concord Drugs reported a strong performance for Q1 FY27, with standalone revenue reaching ₹20.90 Cr, a 56% increase from ₹13.38 Cr in the same quarter last year. Net profit saw a significant jump to ₹1.11 Cr compared to just ₹0.11 Cr in Q1 FY26. This growth is particularly notable as it outpaced a 33% equity dilution resulting from a preferential allotment of 31.75 lakh shares earlier in 2026. The company's quarterly profit now nearly matches its entire TTM PAT of ₹1.06 Cr, indicating a sharp improvement in operational efficiency.
- Standalone Revenue from operations grew 56% YoY to ₹20.89 Cr.
- Standalone Net Profit increased nearly 10x YoY to ₹1.11 Cr from ₹0.11 Cr.
- EPS improved to ₹0.84 despite a 33% increase in equity share capital following a preferential issue.
- Preferential allotment of 31,75,000 equity shares was completed at ₹36.50 per share.
- Consolidated revenue includes a small contribution of ₹36.54 lakhs from subsidiary Proton Remedies Private Limited.
Concord Drugs Ltd has scheduled a board meeting on August 10, 2026, to approve its unaudited financial results for the quarter ended June 30, 2026. The company is coming off a high-growth FY26 where revenue reached Rs 78.77 Cr, nearly doubling from FY25. However, with a TTM PAT of only Rs 1 Cr and a high P/E of 84.1, the upcoming results are critical to justify current valuations. The trading window remains closed for designated persons until 48 hours post-announcement.
- Board meeting scheduled for August 10, 2026, to approve Q1 results
- Results cover the three-month period ended June 30, 2026
- Trading window closed for designated persons as per insider trading norms
- Company reported TTM revenue of Rs 79 Cr as of the latest full year
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
